|
Feb 14
|
Genmab Publishes 2023 Annual Report
|
|
Jan 23
|
Genmab Announces Net Sales of DARZALEX® (daratumumab) for 2023
|
|
Jan 22
|
Genmab Announces Decision in Arbitration Appeal under License Agreement with Janssen
|
|
Jan 19
|
Genmab A/S Sponsored ADR (GMAB) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
|
|
Jan 9
|
GMAB or TECH: Which Is the Better Value Stock Right Now?
|
|
Jan 9
|
TIVDAK® Supplemental Biologics License Application Accepted for Priority Review by FDA for Patients with Recurrent or Metastatic Cervical Cancer
|
|
Jan 9
|
TIVDAK® (tisotumab vedotin-tftv) Supplemental Biologics License Application Accepted for Priority Review by U.S. Food and Drug Administration for Patients with Recurrent or Metastatic Cervical Cancer
|
|
Dec 12
|
Genmab to Hold 2023 R&D Update and ASH Data Review Meeting
|
|
Dec 9
|
New Pivotal Data for Bispecific Antibody Epcoritamab (DuoBody® CD3xCD20) Demonstrates High Overall and Complete Responses in Patients with Hard-To-Treat Relapsed/Refractory Follicular Lymphoma (FL)
|
|
Dec 9
|
New Data for Bispecific Antibody Epcoritamab (DuoBody® CD3xCD20) Shows Strong, Durable Treatment Response for Patients with Difficult-To-Treat Relapsed/Refractory (R/R) Follicular Lymphoma (FL)
|
|
Dec 7
|
HRMY or GMAB: Which Is the Better Value Stock Right Now?
|
|
Dec 5
|
Capital Increase in Genmab as a Result of Employee Warrant Exercise
|
|
Nov 28
|
AbbVie (ABBV) Lymphoma Drug Gets FDA Breakthrough Therapy Tag
|
|
Nov 27
|
Genmab Announces Positive Regulatory Updates for Epcoritamab (EPKINLY®/TEPKINLY®) for the Treatment of Relapsed/Refractory Follicular Lymphoma
|
|
Nov 9
|
Major Shareholder Announcement
|
|
Nov 9
|
Genmab to Present at Jefferies London Healthcare Conference
|
|
Nov 8
|
Genmab A/S (NASDAQ:GMAB) Q3 2023 Earnings Call Transcript
|
|
Nov 7
|
Genmab Announces Financial Results for the First Nine Months of 2023
|